← Eichor
Study identifier: NCT05776251 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

taVNS for Persistent Symptoms From Lyme Disease

Condition: Post-Treatment Lyme Disease  ·  Sponsor: Columbia University

PhaseNA
Planned participants24
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

This study is one of the first studies to investigate a non-antibiotic approach to the treatment of symptoms that persist after antibiotic treatment for Lyme disease (PTLS). Transcutaneous auricular vagus nerve stimulation (taVNS) offers the potential of being an effective and non-toxic approach to reduce the burden of multisystem symptoms in patients with PTLS. This study seeks to address an important goal: to assess the safety, feasibility, and tolerability of a new non-invasive, non-pharmacologic treatment for patients with symptoms that persist despite prior antibiotic treatment for Lyme disease.

This description comes directly from the study's public registry record.

Talk to the study team

Brian A. Fallon, MD  ·  646-774-7503  ·  baf1@cumc.columbia.edu

Mara Kuvaldina, PhD  ·  646-774-7503  ·  mk4480@cumc.columbia.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Lyme and Tick-Borne Diseases Research CenterNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05776251